The phase 3 NRG Oncology GU005 trial of SBRT vs MH-IMRT for intermediate-risk prostate cancer had co-primary endpoints including disease control and patient-reported outcomes.
Intensity-modulated radiation therapy, or IMRT, is a gentler approach to cancer treatment. It aims to destroy cancer while ...
Phase III trial presented at ASTRO in San Francisco finds five-treatment regimen poised to become new standard of care. The principal investigator of the trial, Ellis is a radiation oncologist and ...
Market is entering a decade of transformation, with its global valuation projected to rise from USD 2.6 billion in 2025 to ...
Many things are evaluated when doctors are putting a treatment plan together for prostate cancer patients. A new study says ...
Black men choose aggressive prostate cancer treatment—regardless of anticipated life expectancy—more often than Hispanic or ...
Prostate cancer is the most common cancer among men after skin cancer. Age is a significant risk factor for prostate cancer. Family history and genetic factors play a significant role in prostate ...
News-Medical.Net on MSN
Age impacts systemic therapy outcomes in metastatic prostate cancer
Many things are evaluated when doctors are putting a treatment plan together for prostate cancer patients. A new study says ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback